It's the time of year when the days are short and dark, bears are hibernating, fires are burning and people are exclaiming, "Where did the year go?" Alas, we can't answer that question. What we can offer are a few hints about how the year went. Five hints, to be exact, in the form of FiercePharma's 5 best-read stories of 2013.
Tantalized by various megablockbuster projections for the PCSK9 field of cholesterol drugs, Pfizer has mapped out one of the most ambitious late-stage programs in the industry for RN-316. This week, the pharma giant spelled out plans for a massive cardiovascular outcomes trial to prove to regulators and payers alike that the drug not only works as advertised, but delivers real value to patients.
Three years ago, the Fierce Life Sciences team launched FierceMedicalDevices to provide more coverage in the medtech space. Now we're expanding yet again with the launch of our newest publication, FierceDiagnostics.
The prevalence of diabetes is growing globally, and with that the size of the diabetes drug market. But the market has gotten increasingly competitive and increasingly complex. All of the top 10 best-selling drugs in the diabetes category are blockbusters, according to EvaluatePharma. So who makes them? Check out the report >>
FiercePharma has launched a LinkedIn group. We'd like you to join. Share the news of the day with us. Chat about trends and problems. Suggest story topics, nominate your companies and colleagues for special reports. Tell us your office jokes, even. War stories are great, too. We'll also be soliciting your opinions about the latest issues. Join the group here.
Many of the executives prowling the corridors and holding confabs at the J.P. Morgan Healthcare Conference this week viewed their own companies as well-positioned and saw a lot to like about what will happen this year.
As in years past, we're using our last newsletter issue of the year to dissect the 5 trends we expect to prove important, fascinating and perhaps both, over the next 12 months.
As anyone in pharma knows, data can be a wonderful thing. Crunching data can also be addictive, like kettle corn or tortilla chips. We here at FierceMarkets can spend hours consuming statistics about our readers and web traffic. Here are the stories that garnered the most web traffic over the past 12 months. More >>